Neurological Effects after Chemical Nerve Agent Exposures Workshop

February 26-27, 2014
Neuroscience Center Building (NSC)
6001 Executive Boulevard
Bethesda, Maryland

Sponsored by:
CounterACT Program, Office of the Director, NIH, DHHS
National Institute of Neurological Disorders and Stroke, NIH, DHHS
CONTENTS

1  Introduction
2  Acknowledgements
3  Agenda
7  Logistics
9  Roundtable Assignments
10  Participants
INTRODUCTION

The HHS Office of the Assistant Secretary of Preparedness and Response (ASPR) and Department of Defense (DoD) have large multi-agency programs on the development of better medical countermeasures against chemical threat agents. NIH is charged with basic and translational research in this area. To this end, the NINDS\(^1\) has led the NIH Countermeasures Against Chemical Threats (CounterACT) Program since 2006, with oversight from NIAID\(^2\), and partnerships with several other NIH Institutes including NIEHS\(^3\), NIAMS\(^4\), NEI\(^5\), NICHD\(^6\), NIGMS\(^7\) and NLM\(^8\).

The ASPR develops Scenario-Based and Product-Specific Requirement Documents that help set the NIH research priorities. Currently, HHS is developing such documents for therapeutics that could prevent or reduce the short- and long-term effects of acute, non-lethal exposures to organophosphorus (OP) nerve agents including chemical weapons such as sarin, and pesticides such as parathion. Within ASPR, the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) is exploring the existing clinical data of non-lethal nerve agent exposure and associated long-term neurological sequelae. The relevance of these anecdotal clinical reports is not known, but it is clear that in order for researchers in this field to adopt best practices, the animal models they develop and use to examine the non-lethal neurological effects of nerve agent exposure should be relevant to those observed in humans.

The goal of this workshop is to inform the scientific community on the availability of human and animal data supporting neurological effects after non-lethal exposure to nerve agents, and how these data could be used to develop the best animal models for testing therapeutics.

PRIMARY WORKSHOP QUESTIONS

1. What is the evidence in humans for neurological effects after sub-lethal exposure to OP nerve agents?

2. What animal models exist for neurological effects after sub-lethal exposure to OP nerve agents, and what is the evidence that these effects occur in animals?

3. How do we improve the validity of animal models used for testing potential therapeutics?

4. Can we learn more about appropriate assessment tools and animal models from other types of acute brain injury such as seizures, TBI, or large-vessel stroke?

\(^1\) National Institute of Neurological Disorders and Stroke
\(^2\) National Institute of Allergy and Infectious Diseases
\(^3\) National Institute of Environmental Health Sciences
\(^4\) National Institute of Arthritis and Musculoskeletal and Skin Diseases
\(^5\) National Eye Institute
\(^6\) Eunice Kennedy Shriver National Institute of Child Health and Human Development
\(^7\) National Institute of General Medical Sciences
\(^8\) National Library of Medicine
ACKNOWLEDGEMENTS

The workshop organizers would like to thank the following people for their work and contributions to the meeting program:

WORKSHOP PLANNING COMMITTEE

W. Kent Anger, PhD | Oregon Health & Science University
Steven Bird, MD | University of Massachusetts Medical School
Luciana Borio, MD | Office of Counterterrorism and Emerging Threats, FDA, DHHS
Maria Braga, DDS, PhD | Uniformed Services University of the Health Sciences
Douglas Cerasoli, PhD | U.S. Army Medical Research Institute of Chemical Defense
Susan Cibulsky, PhD | Office of the Assistant Secretary for Preparedness and Response, DHHS
Raymond Dingledine, PhD | Emory University
Byron Ford, PhD | Morehouse School of Medicine
Mark Kirk, MD | Chemical Defense Program, OHA, DHS
Judith Laney, PhD | Office of the Assistant Secretary for Preparedness and Response, DHHS
Pamela Lein, PhD | University of California, Davis
Brad Leissa, MD | Office of Counterterrorism and Emerging Threats, FDA, DHHS
James Madsen, MD, MPH | U.S. Army Medical Research Institute of Chemical Defense
John McDonough, PhD | U.S. Army Medical Research Institute of Chemical Defense
Constance McKee, MBA | i2 Grants Associates, LLC
Michael Rogawski, MD, PhD | University of California, Davis

NIH WORKSHOP ORGANIZERS

David Jett, PhD | Program Director, NIH CounterACT Research, NINDS, NIH
Dave Yeung, PhD | Program Manager, NIH CounterACT Research, NINDS, NIH
Margaret Ochocinska, PhD | Program Specialist, NIH CounterACT Research, NINDS, NIH
Marilyn Johnson | Operations Coordinator, NIH CounterACT Research, NINDS, NIH
AGENDA, Wednesday, February 26

7:00 AM  
*Welcome and Registration*

General Session I (Conference Room C, 1st Floor)

8:00 AM  
*Welcome*  
Story Landis, PhD  
Director, NINDS

*Goals and Objectives*  
David Jett, PhD  
Program Director, NIH CounterACT Research, NINDS, NIH

8:20 AM  
*HHS Research Requirements*  
Susan Cibulsky, PhD  
Office of the Assistant Secretary for Preparedness and Response

8:40 AM  
*FDA Perspective*  
Luciana Borio, MD  
FDA Assistant Commissioner for Counterterrorism Policy

9:00 AM  
*The Animal Rule*  
Andrea Powell, PhD  
FDA CDER Office of Counter-Terrorism and Emergency Coordination

9:45 AM  
*Break*  
*Coffee and refreshments available in the NSC Cafeteria, 1st floor.*

10:00 AM  
*Overview of Human Effects of Nerve Agents*  
Steven Bird, MD  
University of Massachusetts Medical School

10:30 AM  
*Overview of Animal Studies*  
Pamela Lein, PhD  
University of California, Davis

11:00 AM  
*Panel Discussion with Morning Presenters*  
Moderator: David Jett, PhD
AGENDA, Wednesday, February 26– cont’d

12:00 PM  
*Lunch*

*Pre-ordered boxed lunches available in Conference Room E.*

**Breakout Sessions**

1:00 PM  
*Breakout Session I (Conference Room 2172, 2nd Floor)*

*Evidence for Neurological Effects in Humans*

Discussion of the evidence for short- and long-term sub-lethal effects from OP exposures in humans, including neuropathological effects and functional deficits (cognitive, sensory, motor). What is the evidence, and what is the relationship between these chemical exposures and the effects observed (causal, correlational, association, none)?

Session Chair: Steven Bird, MD

*Breakout Session II (Conference Room D, 1st Floor)*

*Evidence for Neurological Effects in Animals*

Discussion of what animal models exist for short- and long-term sub-lethal effects from chemical exposures, including neuropathological effects and functional deficits. What is the predictive value of animal models, both in terms of the effect of the chemical toxin, and the efficacy of potential therapeutics in humans?

Session Co-Chairs: Douglas Cerasoli, PhD and Pamela Lein, PhD

2:45 PM  
*Meeting of Workshop Session Chairs (Conference Room 2172, 2nd Floor)*

2:45 PM  
*Break*

*Coffee and refreshments available in the NSC Cafeteria, 1st floor.*

**General Session II (Conference Room C, 1st Floor)**

*Breakout Session Reports*

3:15 PM  
*Evidence for Neurological Effects in Humans*

Steven Bird, MD
AGENDA, Wednesday, February 26– cont’d

3:25 PM  
Evidence for Neurological Effects in Animals  
Douglas Cerasoli, PhD and Pamela Lein, PhD

4:00 PM  
Comparison of Human and Animal Data  
Discussion of differences and similarities between the effects seen in humans, and the data from animal models of OP toxicity. These will be discussed in the context of developing animal models that are more predictive of the effects seen in humans.

   Session Co-Chairs: W. Kent Anger, PhD and Mark Kirk, MD

5:00 PM  
Lessons Learned from a Neuroprotectant Study: Neuregulin  
Byron Ford, PhD  
Morehouse School of Medicine

5:30 PM  
Adjourn

6:30 PM  
Workshop Dinner  
Timpano Italian Chophouse
AGENDA, Thursday, February 27

7:00 AM  Welcome and Registration

General Session I (Conference Room C, 1st Floor)

8:00 AM  Tokyo Video and Discussion
Tetsu Okumura, MD, PhD
Superintendent Chief of the doctor's office,
Metropolitan Police Academy, Tokyo Metropolitan Police Agency
Tokyo, Japan

8:30 AM  Welcome
Nicole Lurie, MD, MSPH
Assistant Secretary for Preparedness and Response
Rear Admiral, U.S. Public Health Service
U.S. Department of Health and Human Services

8:35 AM  Global OP Poisonings
Nicholas Buckley, BMed, MD, FRACP
Professor, Prince of Wales Clinical School
University of New South Wales
Sydney, Australia

General Session II (Conference Room C, 1st Floor)

9:00 AM  Working Groups and Workshop Deliverables
David Jett, PhD

9:05 AM  Working Group on Animal Model Best Practices
Session Co-Chairs: Pamela Lein, PhD and John McDonough, PhD

10:30 AM  Break

10:45 AM  Working Group on Research Gaps
Session Co-Chairs: Maria Braga, DDS, PhD, and Mark Kirk, MD

12:15 PM  Wrap Up and Way Ahead
David Jett, PhD and Margaret Ochocinska, PhD

12:30 PM  Adjourn Workshop
LOGISTICS

Breakout Sessions | Breakout sessions are planned to convene at 1:00 PM on the first day of the workshop. **Breakout Session I: Evidence for Neurological Effects in Humans** will meet in Conference Room 2172 on the 2nd floor. Signs will guide you to the session.

**Breakout Session II: Evidence for Neurological Effects in Animals** will meet in Conference Room D, just next to Conference Room C where the main session will take place.

The roundtable participants for the sessions have been pre-assigned; please refer to the **Roundtable Assignments** section of this program booklet. Participants who have not been pre-assigned are welcome to attend the session of their choice, space permitting.

Lunch and Refreshments | The following food options have been made available for your convenience:

**Boxed lunches:** If you pre-ordered a boxed lunch through the NIH website, you can collect it in Conference Room E (where you checked in) at 12:00 PM on the first meeting day.

**NSC Facilities:** The NSC Cafeteria, located on the first floor, will be open for breaks and coffee until 4 PM on Wednesday, and through the entire duration of the meeting on Thursday. Please note that the NSC Cafeteria will only accept cash; there is an ATM in the lobby. Additionally, the convenience store on the first floor operates from 7:30 AM to 3:30 PM and also accepts credit cards.

Workshop Dinner | A dinner will take place Wednesday night, 6:30 PM, at Timpano Italian Chophouse, located at 12021 Rockville Pike, Rockville, MD 20852. The meal will cost $36 including tax and gratuities. Participants must bring cash for payment; **credit cards and checks are not accepted**. Please also note that seating is limited in the dining area and may not be available to participants arriving late.

NSC Parking | If you wish to request a parking pass and were not provided one at check-in, please inform a staff member at the Welcome Desk.

Return to Airport | Staff at the Welcome Desk will be available to assist you in booking any necessary return transportation to the airport.
LOGISTICS—cont’d

Shuttle Service Between Hotel and Meeting Venue | For participants staying at the Bethesda North Marriott Hotel and Conference Center, there will be a shuttle to take you from the hotel to the meeting site each day. Please refer to your hotel welcome materials for the schedule indicating which shuttles you should take. The shuttle schedule is as follows:

Day 1, February 26:

7:15 AM – Shuttle 1 from Marriott to NSC
7:30 AM – Shuttle 2 from Marriott to NSC
5:45 PM – Shuttle 1 from NSC to Marriott
6:00 PM – Shuttle 2 from NSC to Marriott

Day 2, February 27:

7:15 AM – Shuttle 1 from Marriott to NSC
7:30 AM – Shuttle 2 from Marriott to NSC

There will be no return shuttle to the hotel on the second day, so please remember to bring your luggage to the meeting. We will watch your bags at the Welcome Desk in Conference Room E.
ROUND TABLE ASSIGNMENTS

BREAKOUT SESSION I: EVIDENCE FOR NEUROLOGICAL EFFECTS IN HUMANS

Conference Room 2172

Session Chair: Steven Bird, MD

Roundtable Assignments:

W. Kent Anger, PhD
Thomas Bleck, MD
Luciana Borio, MD
Francesca Bosetti, PhD
Nicholas Buckley, BMed, MD, FRACP
Charles C. Engel, MD, MPH
Brandy Fureman, PhD
Frederick Henretig, MD
Daryl Hood, PhD
David Jett, PhD
Marti Jett, PhD

Mark Kirk, MD
Walter Koroshetz, MD
Roger McIntosh, MD, MOH
Margaret Ochocinska, PhD
Tetsu Okumura, MD, PhD
Michael Rogawski, MD, PhD
Diane Rohlman, PhD
David Siegel, MD
Shedra Snipes, PhD
Ernie Takafuji, MD
Paul Wax, MD

BREAKOUT SESSION II: EVIDENCE FOR NEUROLOGICAL EFFECTS IN ANIMALS

Conference Room D

Session Co-Chairs: Douglas Cerasoli, PhD
Pamela Lein, PhD

Roundtable Assignments:

Edson Albuquerque, MD, PhD
Mike Babin, DVM, PhD
Jim Blank, PhD
Maria Braga, DDS, PhD
Philip Bushnell, PhD
Anthony Choo, PhD
Robert DeLorenzo, MD, PhD, MPH
Franck Dhote, DVM, PhD
Ray Dingedine, PhD
C. Edward Dixon, PhD
Byron Ford, PhD
Joseph Hanig, PhD

Eng Lo, PhD
Elizabeth Maull, PhD
John McDonough, PhD
Miguel Perez-Pinzon, PhD
Carey Pope, PhD
Wendy Pouliot, PhD
Rajesh Ranganathan, PhD
D. Samba Reddy, PhD, RPH
Richard Rotundo, PhD
Alvin Terry, Jr, PhD
Karen Wilcox, PhD
Dave Yeung, PhD
PARTICIPANTS

William Albrecht, PhD, MPH  
National Biosurveillance Integration Center, DHS  
Email: william.albrecht@hq.dhs.gov

Edson Albuquerque, MD, PhD  
University of Maryland  
Email: ealbuquerque@som.umaryland.edu

Wyndham Anger, PhD  
Oregon Health & Science University  
Email: anger@ohsu.edu

Houmam Araj, PhD  
National Eye Institute, NIH, DHHS  
Email: lens@nih.gov

Michael Babin, DVM, PhD  
Battelle Memorial Institute  
Email: babinm@battelle.org

Benjamin Baccus, MD, PhD  
French Army Health Service  
Email: benjamin.baccus@irba.fr

Bill Basinger, MS  
Countervail Corporation  
Email: bbasinger@countervailcorp.com

Steven Bird, MD  
University of Massachusetts  
Email: steven.bird@umassmedical.org

Jim Blank, PhD  
Battelle Memorial Institute  
Email: blankj@battelle.org

Thomas Bleck, MD  
Rush University  
Email: tbleck@gmail.com

Luciana Borio, MD  
Office of Counterterrorism and Emerging Threats, FDA, DHHS  
Email: luciana.borio@fda.hhs.gov

Francesca Bosetti, PhD  
National Institute of Neurological Disorders and Stroke, NIH, DHHS  
Email: frances@mail.nih.gov

Maria Braga, DDS, PhD  
Uniformed Services University of the Health Sciences  
Email: maria.braga@usuhs.edu

Nicholas Buckley, BMed, MD, FRACP  
University of New South Wales  
Email: nbuckley@hypertox.com

Philip Bushnell, PhD  
U.S. Environmental Protection Agency  
Email: bushnell.philip@epa.gov

Douglas Cerasoli, PhD  
U.S. Army Medical Research Institute of Chemical Defense  
Email: douglas.m.cerasoli.civ@mail.mil

Pamela Chamberlain, DVM, DABT, PhD  
Office of Counterterrorism and Emerging Threats, FDA, DHHS  
Email: pamela.chamberlain@fda.hhs.gov
PARTICIPANTS—cont’d

Anthony Choo, PhD
PsychoGenics, Inc.
Email: anthony.choo@psychogenics.com

Sue Cibulsky, PhD
Office of the Assistant Secretary for Preparedness and Response, DHHS
Email: susan.cibulsky@hhs.gov

Rakhi Dalal, PhD
Office of Device Evaluation, FDA, DHHS
Email: rakhi.dalal@fda.hhs.gov

Robert DeLorenzo, MD, PhD, MPH
Virginia Commonwealth University
Email: rdeloren@vcu.edu

Franck Dhote, DVM, PhD
Armed Forces Biomedical Research Institute
Email: franck.dhote@irba.fr

Ray Dingledine, PhD
Emory University
Email: rdingledine@pharm.emory.edu

C. Edward Dixon, PhD
University of Pittsburgh
Email: dixonec@upmc.edu

Charles Engel, MD, MPH
RAND Corporation
Email: cengel@rand.org

Byron Ford, PhD
Morehouse School of Medicine
Email: bford@msm.edu

Brandy Fureman, PhD
National Institute of Neurological Disorders and Stroke, NIH, DHHS
Email: furemanb@ninds.nih.gov

Anthony Garza, MS
Office of Counterterrorism and Emerging Threats, FDA, DHHS
Email: anthony.garza@fda.hhs.gov

Amy Ghering, PhD
Office of In Vitro Diagnostics and Radiological Health, FDA, DHHS
Email: amy.ghering@fda.hhs.gov

Douglas Gibson, PhD, MA
U.S. Army Medical Research and Materiel Command
Email: douglas.b.gibson.civ@mail.mil

Alan Goldberg
Office of the Assistant Secretary for Preparedness and Response, DHHS
Email: alan.goldberg@hhs.gov

Pertti (Bert) Hakkinen, Ph.D.
National Library of Medicine, NIH, DHHS
Email: pertti.hakkinen@nih.gov

Joseph Hanig, PhD
Office of Testing and Research, FDA, DHHS
Email: joseph.hanig@fda.hhs.gov

Benjamin Hatten, MD, MPH
American College of Medical Toxicology
Email: benjamin.hatten@gmail.com
PARTICIPANTS— cont’d

Fred Henretig, MD
Children’s Hospital of Philadelphia
Email: henretig@email.chop.edu

Kristen Herring, PhD
Defense Threat Reduction Agency, DoD
Email: kristen.herring@dtra.mil

Darryl Hood, PhD
The Ohio State University
Email: dhood@cph.osu.edu

Angela Jackson, PhD
Office of the Assistant Secretary for Preparedness and Response, DHHS
Email: angela.jackson@hhs.gov

David Jett, PhD
National Institute of Neurological Disorders and Stroke, NIH, DHHS
Email: jettd@ninds.nih.gov

Marti Jett, PhD
U.S. Army Medical Research and Materiel Command
Email: marti.jett-tilton.civ@gmail.mil

Mark Kirk, MD
Chemical Defense Program, DHS
Email: mark.kirk@hq.dhs.gov

Walter Koroshetz, MD
National Institute of Neurological Disorders and Stroke, NIH, DHHS
Email: koroshetzw@ninds.nih.gov

Mara Kreishman-Deitrick, PhD
U.S. Army Medical Research and Materiel Command
Email: mara.deitrick@fda.hhs.gov

Story Landis, PhD
National Institute of Neurological Disorders and Stroke, NIH, DHHS
Email: LandisS@ninds.nih.gov

Judy Laney, PhD
Office of the Assistant Secretary for Preparedness and Response, DHHS
Email: judith.laney@hhs.gov

Lucille Lange, PhD
U.S. Army Medical Research Institute of Chemical Defense
Email: lucille.a.lange.civ@mail.mil

Pamela Lein, PhD
University of California, Davis
Email: pjlein@ucdavis.edu

Brad Leissa, MD
Office of Counterterrorism and Emergency Coordination, FDA, DHHS
Email: brad.leissa@fda.hhs.gov

Alicia Livinski, MPH, MA
National Institutes of Health Library, NIH, DHHS
Email: alicia.livinski@nih.gov

Eng Lo, PhD
Massachusetts General Hospital
Email: lo@helix.mgh.harvard.edu
PARTICIPANTS—cont’d

Nicole Lurie, MD, MSPH  
Office of the Assistant Secretary for Preparedness and Response, DHHS  
Email: LandisS@ninds.nih.gov

Renae Malek, PhD  
Chemical Defense Pharmaceuticals  
Email: renae.l.malek.civ@mail.mil

Ronald Manning, PhD  
Office of the Assistant Secretary for Preparedness and Response, DHHS  
Email: ronald.manning@hhs.gov

Elizabeth Maull, PhD  
National Institute of Environmental Health Sciences, NIH, DHHS  
Email: maull@niehs.nih.gov

Elaine Mayhall, PhD  
Office of Device Evaluation, FDA, DHHS  
Email: elaine.mayhall@fda.hhs.gov

Susan McDermott, MD  
Office of Counterterrorism and Emergency Coordination, FDA, DHHS  
Email: susan.mcdermott@fda.hhs.gov

John McDonough, PhD  
U.S. Army Medical Research Institute of Chemical Defense  
Email: john.h.mcdonough2.civ@mail.mil

Roger McIntosh, MD, MOH  
U.S. Army Public Health Command  
Email: roger.g.mcintosh.civ@mail.mil

Constance McKee, MBA  
i2 Grants Associates, LLC  
Email: constance@i2grantsassociates.com

Eric Moore, PhD  
Defense Threat Reduction Agency, DoD  
Email: eric.moore@dtra.mil

Christina Niemeyer, PhD  
i2 Grants Associates, LLC  
Email: christina@i2grantsassociates.com

Margaret Ochocinska, PhD  
National Institute of Neurological Disorders and Stroke, NIH, DHHS  
Email: ochocinm@mail.nih.gov

Tetsu Okumura, MD, PhD  
Tokyo Metropolitan Police Academy  
Email: feokumura@mac.com

Miguel Perez-Pinzon, PhD  
University of Miami  
Email: perezpinzon@med.miami.edu

Gennady Platoff, PhD  
National Institute of Allergy and Infectious Diseases, NIH, DHHS  
Email: gennady.platoff@nih.gov

Carey Pope, PhD  
Oklahoma State University  
Email: carey.pope@okstate.edu

Wendy Pouliot, PhD  
University of Utah  
Email: wendy.pouliot@hsc.utah.edu
PARTICIPANTS—cont’d

Andrea Powell, PhD
Center for Drug Evaluation and Research, FDA, DHHS
Email: andrea.powell@fda.hhs.gov

Rajesh Ranganathan, PhD
National Institute of Neurological Disorders and Stroke, NIH, DHHS
Email: rajesh.ranganathan@nih.gov

Robert Raulli, PhD
Office of the Assistant Secretary for Preparedness and Response, DHHS
Email: robert.raulli@hhs.gov

D. Samba Reddy, PhD, RPH
Texas A&M University
Email: reddy@medicine.tamhsc.edu

Michael Rogawski, MD, PhD
University of California, Davis
Email: rogawski@ucdavis.edu

Diane Rohlman, PhD
University of Iowa
Email: diane-rohlman@uiowa.edu

Richard Rotundo, PhD
University of Miami
Email: rrotundo@miami.edu

Bruce Schoneboom, PhD, CRNA, FAAN
U.S. Army Medical Research Institute of Chemical Defense
Email: bruce.a.schoneboom.mil@mail.mil

Keith Sharrow, PhD
U.S. Army Public Health Command
Email: keith.sharrow@us.army.mil

David Siegel, MD
Eunice Kennedy Shriver National Institute of Child Health, NIH, DHHS
Email: siegelda@mail.nih.gov

Shedra Snipes, PhD
Pennsylvania State University
Email: sas84@psu.edu

Ernest Takafuji, MD
National Institute of Allergy and Infectious Diseases, NIH, DHHS
Email: etakafuji@niaid.nih.gov

Alvin Terry, Jr., PhD
Georgia Regents University
Email: jdavis2@gru.edu

Brian Tse, PhD
Office of the Assistant Secretary for Preparedness and Response, DHHS
Email: brian.tse@hhs.gov

Patrick Twoney, MD
U.S. Army Medical Research and Materiel Command
Email: patrick.s.twoney.mil@mail.mil
PARTICIPANTS— cont’d

Ed Wakayama, PhD
Office of the Assistant Secretary for
    Preparedness and Response, DHHS
Email: ed.wakayama@hhs.gov

Yushan Wang, MD, PhD
Defense Research and Development Canada,
    DND
Email: yushan.wang@drdc-rddc.gc.ca

Paul Wax, MD
American College of Medical Toxicology
Email: paul.wax@me.com

Elaine Wencil, PhD
U.S. Department of Health and Human Services
Email: elaine.wencil@hhs.gov

Karen Wilcox, PhD
University of Utah
Email: karen.wilcox@hsc.utah.edu

Linnzi Wright, PhD
U.S. Army Medical Research Institute of
    Chemical Defense
Email: linnzi.k.wright.ctr@mail.mil

Dave Yeung, PhD
National Institute of Neurological Disorders and
    Stroke, NIH, DHHS
Email: dy70v@nih.gov

Debra Yourick, PhD
U.S. Army Medical Research and Materiel
    Command
Email: debra.l.yourick.civ@mail.mil